HemaSphere
(Jun 2022)
PB2354: THE IMPACT OF ACUTE HEPATIC PORPHYRIA ON MENTAL HEALTH: RESULTS FROM THE PORPHYRIA WORLDWIDE PATIENT EXPERIENCE RESEARCH (POWER) STUDY
- D. Nance,
- D. Lyon,
- S. Hegarty,
- R. Falchetto,
- J. Barman-Aksözen,
- J. E. Matos,
- S. Meninger,
- S. Lombardelli,
- A. Dickey
Affiliations
- D. Nance
- 1 Banner Health, Gilbert
- D. Lyon
- 2 American Porphyria Foundation, Bethesda, United States of America
- S. Hegarty
- 3 Global Porphyria Advocacy Coalition, Durham City, United Kingdom
- R. Falchetto
- 4 Swiss Society for Porphyria
- J. Barman-Aksözen
- 4 Swiss Society for Porphyria
- J. E. Matos
- 6 Cerner Enviza, North Kansas City
- S. Meninger
- 7 Alnylam Pharmaceuticals, Cambridge, United States of America
- S. Lombardelli
- 8 Alnylam Pharmaceuticals, Maidenhead, United Kingdom
- A. Dickey
- 9 Massachusetts General Hospital, Boston, United States of America
- DOI
-
https://doi.org/10.1097/01.HS9.0000852240.72002.e6
- Journal volume & issue
-
Vol. 6
pp.
2223
– 2224
WeChat QR code